US Patent

US9968553 — Enalapril compositions

Method of Use · Assigned to University of Kansas · Expires 2032-11-06 · 6y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable enalapril powder compositions for oral liquid formulation and methods of using them to treat hypertension, heart failure, and asymptomatic left ventricular dysfunction.

USPTO Abstract

Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.

Drugs covered by this patent

Vasotec (ENALAPRIL MALEATE) · Azurity

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-71`	—	Vasotec

Patent Metadata

Patent number: US9968553
Jurisdiction: US
Classification: Method of Use
Expires: 2032-11-06
Drug substance claim: No
Drug product claim: No
Assignee: University of Kansas
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.